Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
暂无分享,去创建一个
M. Boccadoro | V. Callea | F. Ferrara | E. Zamagni | V. De Stefano | M. Marcatti | P. Musto | R. Zambello | A. Palumbo | M. Petrucci | C. Nozzoli | F. Patriarca | M. Cavo | A. Carella | G. Perrone | A. Baraldi | L. Masini | A. Falcone | A. Brioli | D. Derudas | M. Dessanti | L. Pantani | A. Pezzi | S. Ballanti | C. Crippa | M. Grasso | C. Califano | A. Nozza | D. Donnarumma | A. Furlan
[1] G. Morgan,et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. , 2012, Blood.
[2] B. Pégourié,et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. , 2011, Blood.
[3] B. Pégourié,et al. Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program , 2011 .
[4] M. Dimopoulos,et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. , 2011, Blood.
[5] D. Esseltine,et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.
[6] M. Baccarani,et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.
[7] J. Miguel,et al. A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib , 2010 .
[8] P. Moreau,et al. Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02. , 2010 .
[9] K. Owzar,et al. Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104 , 2010 .
[10] M. Kersten,et al. HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM) , 2010 .
[11] P. Moreau,et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Mohty,et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Esseltine,et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.
[14] J. Crowley,et al. Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Chanan-Khan,et al. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Boccadoro,et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Sonneveld,et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. , 2010, Blood.
[18] M. Boccadoro,et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Baccarani,et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] H. Avet-Loiseau,et al. The role of complete response in multiple myeloma. , 2009, Blood.
[21] J. Harousseau. Maintenance therapy in multiple myeloma , 2009, Hematology Reviews.
[22] D. Reece,et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. , 2008, Cancer treatment reviews.
[23] H. van de Velde,et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma , 2007, Haematologica.
[24] M. Baccarani,et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[26] John Crowley,et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. , 2006, Blood.
[27] M. Baccarani,et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. , 2005, Blood.
[28] J. Crowley,et al. International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[30] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[31] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[32] B. Barlogie,et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.
[33] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[34] N. Nahi,et al. Improved progression free survival with bortezomib consolidation after high dose melphalan: results of a randomised phase III trial , 2011 .
[35] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2007, Leukemia.
[36] J. Rossi,et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.